Discounted Cash Flow
Gilead Sciences, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $30.4b | $13.5b | $15.9b | 44.4% | $10.08 |
| 2017 | $26.1b (-14.1%) | $4.6b (-65.7%) | $11.3b (-29.0%) | 17.7% (-60.1%) | $3.54 (-64.9%) |
| 2018 | $22.1b (-15.2%) | $5.5b (17.9%) | $7.5b (-33.9%) | 24.7% (39.1%) | $4.20 (18.6%) |
| 2019 | $22.4b (1.5%) | $5.4b (-1.3%) | $8.3b (11.3%) | 24.0% (-2.7%) | $4.24 (1.0%) |
| 2020 | $24.7b (10.0%) | $123.0m (-97.7%) | $7.5b (-9.6%) | 0.5% (-97.9%) | $0.10 (-97.6%) |
| 2021 | $27.3b (10.6%) | $6.2b (4961.0%) | $10.8b (43.7%) | 22.8% (4476.1%) | $4.96 (4860.0%) |
| 2022 | $27.3b (-0.1%) | $4.6b (-26.2%) | $8.3b (-22.8%) | 16.8% (-26.2%) | $3.66 (-26.2%) |
| 2023 | $27.1b (-0.6%) | $5.7b (23.4%) | $7.4b (-11.1%) | 20.9% (24.1%) | $4.54 (24.0%) |
| 2024 | $28.8b (6.0%) | $480.0m (-91.5%) | $480.0m (-93.5%) | 1.7% (-92.0%) | $0.38 (-91.6%) |
| 2025 | $29.4b (2.4%) | $8.5b (1672.9%) | $9.5b (1870.0%) | 28.9% (1631.4%) | $6.84 (1700.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.